Dr. Hu Kai

• Chief Physician, Director of Adult Lymphoma/Myeloma, Beijing GoBroad Boren Hospital (2019–present)

• Deputy Director and Associate Chief, Hematology, Peking University Third Hospital (2005–2019)

• Expertise in multidisciplinary care for hematological malignancies, stem cell transplantation, and immunotherapy

• PI and collaborator on 40+ clinical trials and over 100 studies

• Completed over 500 CAR-T therapy cases for relapsed/refractory lymphoma/myeloma

• First/corresponding author for 40+ published papers; co-authored 5 books

• Chairman, Precision Diagnosis & Treatment Committee for Hematologic Oncology, Beijing Health Promotion Association

• Conference chair/speaker at major national and international hematology/oncology conferences

Dr. Hu Kai is one of China’s foremost experts in hematology-oncology, recognized for innovation in CAR-T cell immunotherapy, stem cell transplantation, and molecular diagnosis of lymphoma and myeloma. He leads clinical and research efforts at Beijing GoBroad Boren Hospital, where he has completed hundreds of advanced cellular therapies and published widely in international journals. As a leader in hematologic cancer care, Dr. Hu directs multicenter trials, educates fellow specialists, and serves as chair or member in expert national committees, advancing patient outcomes through high-level translational research.